| Human papillomavirus and oropharynx cancer: biology, detection and clinical implications CT Allen, JS Lewis Jr, SK El‐Mofty, BH Haughey, B Nussenbaum The Laryngoscope 120 (9), 1756-1772, 2010 | 216 | 2010 |
| Inhibition of MDSC trafficking with SX-682, a CXCR1/2 inhibitor, enhances NK-cell immunotherapy in head and neck cancer models S Greene, Y Robbins, WK Mydlarz, AP Huynh, NC Schmitt, J Friedman, ... Clinical Cancer Research 26 (6), 1420-1431, 2020 | 212 | 2020 |
| Anti-PD-L1 efficacy can be enhanced by inhibition of myeloid-derived suppressor cells with a selective inhibitor of PI3Kδ/γ RJ Davis, EC Moore, PE Clavijo, J Friedman, H Cash, Z Chen, C Silvin, ... Cancer research 77 (10), 2607-2619, 2017 | 212 | 2017 |
| Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy L Sun, PE Clavijo, Y Robbins, P Patel, J Friedman, S Greene, R Das, ... JCI insight 4 (7), 2019 | 209 | 2019 |
| Somatic Mutations in UBA1 Define a Distinct Subset of Relapsing Polychondritis Patients With VEXAS MA Ferrada, KA Sikora, Y Luo, KV Wells, B Patel, EM Groarke, ... Arthritis & Rheumatology 73 (10), 1886-1895, 2021 | 174 | 2021 |
| Cisplatin alters antitumor immunity and synergizes with PD-1/PD-L1 inhibition in head and neck squamous cell carcinoma L Tran, CT Allen, R Xiao, E Moore, R Davis, SJ Park, K Spielbauer, ... Cancer immunology research 5 (12), 1141-1151, 2017 | 159 | 2017 |
| Sicca syndrome associated with immune checkpoint inhibitor therapy BM Warner, AN Baer, EJ Lipson, C Allen, C Hinrichs, A Rajan, E Pelayo, ... The oncologist 24 (9), 1259-1269, 2019 | 155 | 2019 |
| ΔNp63 versatilely regulates a Broad NF-κB gene program and promotes squamous epithelial proliferation, migration, and inflammation X Yang, H Lu, B Yan, RA Romano, Y Bian, J Friedman, P Duggal, C Allen, ... Cancer research 71 (10), 3688-3700, 2011 | 150 | 2011 |
| Nuclear factor-κB–related serum factors as longitudinal biomarkers of response and survival in advanced oropharyngeal carcinoma C Allen, S Duffy, T Teknos, M Islam, Z Chen, PS Albert, G Wolf, ... Clinical Cancer Research 13 (11), 3182-3190, 2007 | 144 | 2007 |
| Established T cell–inflamed tumors rejected after adaptive resistance was reversed by combination STING activation and PD-1 pathway blockade E Moore, PE Clavijo, R Davis, H Cash, C Van Waes, Y Kim, C Allen Cancer immunology research 4 (12), 1061-1071, 2016 | 143 | 2016 |
| Role of activated nuclear factor‐κB in the pathogenesis and therapy of squamous cell carcinoma of the head and neck CT Allen, JL Ricker, Z Chen, C Van Waes Head & Neck: Journal for the Sciences and Specialties of the Head and Neck …, 2007 | 141 | 2007 |
| Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer RJ Davis, C Van Waes, CT Allen Oral oncology 58, 59-70, 2016 | 135 | 2016 |
| Galectin-1–driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance DK Nambiar, T Aguilera, H Cao, S Kwok, C Kong, J Bloomstein, Z Wang, ... The Journal of clinical investigation 129 (12), 5553-5567, 2019 | 128 | 2019 |
| Host immunity following near-infrared photoimmunotherapy is enhanced with PD-1 checkpoint blockade to eradicate established antigenic tumors T Nagaya, J Friedman, Y Maruoka, F Ogata, S Okuyama, PE Clavijo, ... Cancer immunology research 7 (3), 401-413, 2019 | 127 | 2019 |
| Antigen processing and presentation in cancer immunotherapy MY Lee, JW Jeon, C Sievers, CT Allen Journal for immunotherapy of cancer 8 (2), 2020 | 116 | 2020 |
| PD-1 blockade reverses adaptive immune resistance induced by high-dose hypofractionated but not low-dose daily fractionated radiation M Morisada, PE Clavijo, E Moore, L Sun, M Chamberlin, C Van Waes, ... Oncoimmunology 7 (3), e1395996, 2018 | 114 | 2018 |
| PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations KP Fabian, MR Padget, RN Donahue, K Solocinski, Y Robbins, CT Allen, ... Journal for immunotherapy of cancer 8 (1), 2020 | 109 | 2020 |
| Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-κB subunits in head and neck cancer C Allen, K Saigal, L Nottingham, P Arun, Z Chen, C Van Waes Clinical Cancer Research 14 (13), 4175-4185, 2008 | 100 | 2008 |
| Aberrant IKKα and IKKβ cooperatively activate NF-κB and induce EGFR/AP1 signaling to promote survival and migration of head and neck cancer LK Nottingham, CH Yan, X Yang, H Si, J Coupar, Y Bian, TF Cheng, ... Oncogene 33 (9), 1135-1147, 2014 | 99 | 2014 |
| Resistance to CTLA-4 checkpoint inhibition reversed through selective elimination of granulocytic myeloid cells PE Clavijo, EC Moore, J Chen, RJ Davis, J Friedman, Y Kim, C Van Waes, ... Oncotarget 8 (34), 55804, 2017 | 90 | 2017 |
